4 Marijuana Stocks Looking to Combat the Opioid Epidemic

The pharmaceutical and biotech industry is tasked with one purpose: to improve the quality of life for people. But, what if that task were being compromised by the medicines they’re creating?

In terms of their clinical results, opioids have shown demonstrably positive impacts on reducing pain associated with a chronic disease, and they are a staple therapy for certain diseases. In 2012, some 259 million prescriptions were written for prescription opioids, which would be enough to ensure that every adult in the U.S. received their own bottle.

Opioids are a highly addictive therapy that, according to the American Society of Addiction Medicine, led to 20,101 overdose-related deaths in 2015.

In fact, the dangers of opioid addiction and overdose-related death have become such a reality that the Food and Drug Administration (FDA) recently requested Endo International take Opana ER, an opioid therapy, off the market.

Continue reading at The Motley Fool